Phase 2 N=40 Extended Dosing With Eltrombopag for Severe Aplastic Anemia
Severe Aplastic Anemia (SAA)
Primary: Number of Participants With Drug Response as Defined by Clinically-signficant Hematologic Improvements — 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies
Prematurity · Intestine Perforation · Necrotizing Enterocolitis (NEC)
Primary: The Serum Biomarkers of Inflammatory Cytokines
Phase 2 N=550 Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
Asthma
Primary: Annualized Asthma Exacerbation Rate (AER) Through Week 52 — 0.72; 0.27; 0.20; 0.23 events per person-year — p=<0.001
Phase 2 N=34 Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
Aging
Primary: Immunological Responses — 8.33; 11.24 cells/mm^3 — p=0.56
Phase 2 N=33 Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy
Diabetic Retinopathy
Primary: The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group — 2.80; 0.13 dB
Phase 2 N=202 Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
Patent Ductus Arteriosus · Surgery · Necrotizing Enterocolitis
Primary: Number of Infants Who Undergo in Hospital PDA Ligations or Who Have an Open Ductus at the Time of Discharge (That Need Future Outpatient Cardiology Follow-up Visits)…
Phase 2 N=28 Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Stage IV Pancreatic Cancer
Primary: Number of Participants With a Dose-limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 2 N=32 Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
Atherosclerosis · Cardiovascular Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 3; 3; 3; 4 Participants
Phase 2 N=8 Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
Infection, Human Immunodeficiency Virus
Primary: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) — 4; 1; 0; 0 Participants
Phase 2 N=46 Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis
Peri-implant Mucositis
Primary: Change in Interleukin 1 B at Base to 24 Hours — -1.075; 1.013 Micrograms per deciliter (ug/dl) — p=0.90
Phase 2 N=61 Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus (RSV)
Primary: Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set — -0.73; -0.90 log10 copies/mL — p=0.72
Phase 2 N=128 Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
Alzheimer Disease
Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236
Phase 2 N=248 A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya
Pneumonia
Primary: Highest Grade of Reactogenicity Events in the Adult Cohort: Vaccination 1 — 11; 12; 22; 1 Participants
Phase 2 N=300 Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants
Tuberculosis
Primary: Number of Subjects With Grade 3 Solicited Local Symptoms After Dose 1, Dose 2 and Across Doses — 0; 0; 0; 0 Participants
Phase 2 N=258 The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity
Obesity
Primary: Percentage Body Weight Change — 1.121; 0.674; -0.489; -0.929 percentage — p=0.5461